glp-1 news today october 16 2025 What's next for innovation: A primer on the race reshaping pharma and chronic disease care McKee's proposed FY2027 budget drops

Linagliptins effects on normal human islets have been examined previously by Shah et al ., in which the investigators have found that linagliptin restores cell function through GLP-1 stabilization 28

In terms of completion of the entire trial, 29 participants were treated with a combined treatment of cagrilintide and semaglutide and treatment with semaglutide by itslef while 30 participants were treated with cagrilintide

According to FDA prescribing information, these effects vary by product and dose: For Ozempic (diabetes treatment): Nausea (15-20% of patients) Diarrhea (8-9% of patients) Vomiting (5-9% of patients) Constipation (3-7% of patients) Abdominal pain (5-6% of patients) For Wegovy (weight management), gastrointestinal effects are more common at the higher therapeutic dose: Nausea (up to 44% of patients) Diarrhea (up to 30% of patients) Vomiting (up to 24% of patients) Constipation (up to 24% of patients) Abdominal pain (up to 20% of patients) These effects are generally mild to moderate and tend to diminish with continued use

Although more cases and studies are required to support a causal relationship, it may be prudent to consider the alternative explanation that the patient coincidentally developed colon cancer of unknown cause and MC within 15 years of anthraquinone laxative use